Document is current
Any future updates will be listed below
-
Authors
Babu, Swathy https://orcid.org/0000-0002-0612-9484
Chen, Jiajia https://orcid.org/0000-0002-5378-6284
Baron, Chloé S. https://orcid.org/0000-0001-8351-4768
Sun, Kaiwen
Robitschek, Emily
McConnell, Alicia M.
Wu, Constance
Dedeilia, Aikaterini
Sade-Feldman, Moshe https://orcid.org/0000-0002-0022-0287
Modhurima, Rodsy
Manos, Michael P. https://orcid.org/0000-0003-0841-207X
Chen, Kevin Y.
Cox, Anna M.
Ludwig, Calvin G. https://orcid.org/0000-0002-1938-4273
Kellis, Manolis https://orcid.org/0000-0001-7113-9630
Buchbinder, Elizabeth I.
Hacohen, Nir https://orcid.org/0000-0002-2349-2656
Yang, Jiekun
Boland, Genevieve M. https://orcid.org/0000-0002-7522-6173
Abraham, Brian J. https://orcid.org/0000-0001-8085-3027
Liu, David https://orcid.org/0000-0003-0346-5033
Zon, Leonard I.
Insco, Megan L. https://orcid.org/0000-0002-6078-6506
-
Funding
Funding for this research was provided by:
Funding sources are included in the manuscript.
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 7 July 2025
First Online: 22 July 2025
Competing interests
: L.I.Z. is a founder and stockholder of Fate Therapeutics, CAMP4 Therapeutics, and Scholar Rock. He is a consultant for Celularity. B.J.A. is a shareholder in Syros Pharmaceuticals. E.I.B. serves as a consultant/advisory board member for Obsidian, Zola, Anaveon, Merck and Werewolf pharmaceuticals. G.M.B. has sponsored research agreements through her institution with: Olink Proteomics, Teiko Bio, InterVenn Biosciences, Palleon Pharmaceuticals, Astellas, and AstraZeneca. She served on advisory boards for: Iovance, Merck, Moderna, Nektar Therapeutics, Novartis, Replimune, and Ankyra Therapeutics. She consults for: Merck, InterVenn Biosciences, Iovance, and Ankyra Therapeutics. She holds equity in Ankyra Therapeutics. The remaining authors declare no competing interests.
